Magellanic Cloud Subsidiary Emerges as L1 Bidder for Bank of Maharashtra Tender Worth Rs.115 Crore
The proposed project could expand Magellanic Cloud’s presence in the banking and financial services sector through its surveillance and security infrastructure business.
Provigil Surveillance Emerges as L1 Bidder
Provigil Surveillance Limited, a wholly owned subsidiary of Magellanic Cloud Limited, has been identified as the L1 bidder for a tender issued by Bank of Maharashtra. The project covers the supply, installation and commissioning of electronic surveillance systems, along with the operation of a 24/7 Central Monitoring Station.
While the L1 status marks a key step in the bidding process, the contract has not yet been formally awarded. According to the company’s filing, the award remains subject to the issuance of an official order by the bank.
Tender Scope and Business Impact
- Estimated bid value: Approximately Rs 115 crore.
- Subsidiary involved: Provigil Surveillance Limited, a wholly owned subsidiary of Magellanic Cloud Limited.
- Tendering authority: Bank of Maharashtra.
- Project coverage: More than 1,550 bank sites.
- Scope of work: Supply, installation and commissioning of electronic surveillance systems.
- Monitoring services: Operation of a Central Monitoring Station on a 24/7 basis.
- Contract status: Provigil Surveillance has emerged as the L1 bidder, with the final award pending a formal order from the bank.
- Strategic significance: The opportunity could strengthen Magellanic Cloud’s presence in the banking, financial services and insurance (BFSI) electronic surveillance segment.
- Business alignment: The project aligns with the company’s existing focus on integrated security infrastructure and surveillance solutions.
What to Watch Next
The next key development will be the formal award of the tender by Bank of Maharashtra. Market participants will also monitor the project’s execution timeline, deployment across the identified bank sites and any further contract-related disclosures from Magellanic Cloud.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed a strategic agreement with Pirelli to expand its presence in India's premium passenger car tyre market. Under the agreement, BKT will produce up to 800,000 Pirelli-branded premium car tyres by 2030. Production will take place at one of BKT's newly constructed plants, equipped with advanced technology and designed to meet Pirelli's quality standards. The agreement also provides for a potential 50-50 joint venture to build a new production plant for high-value car tyres for domestic and international markets. The partnership aims to help both companies benefit from the expected growth in India's premium car tyre market.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.